Close inspection of the swimmers plot shows that 12 patients initially responding to CART-ddBCMA have relapsed, most by around 12 months, and in addition there was one death, though this was unrelated to disease or treatment.Īccordingly, at 18 months the response rate stands at 50% – 11 of 22 patients. However, many of the remissions are not proving durable. This is the same state of play as at the Asco data cutoff. So far so good, and it must also be stressed that safety remains relatively clean: among grade 3 events there is just one cytokine release syndrome and two neurotoxicity cases. ![]() The EBITDA loss represents an improvement of 383. Operating loss (EBIT) ended at 3,311 mDKK and is in line with the guidance of an operating loss (EBIT) of 3.1-3.3 bDKK announced beginning of 2022. Kites recent Investors Day 100+ slide powerpoint presentation presents a compelling case for this companys future. The revenue growth in constant currency rates was 4 and in-line with guidance of 3-5 for the year. And 27 of those 38 responses are complete. Kite Pharma is an aptly named company and a solid player in gene therapy. (Nasdaq:KITE) today provided a corporate update and reported fourth quarter and full-year 2016 financial results for the period ended December 31, 2016. All 31 patients previously detailed had gone into remission, and so have the extra seven patients now presented. Go as Senior Director, Clinical Development and Jeff Aycock as Senior Director, Clinical Operations. ![]() This was on the basis of efficacy in line with Carvykti in an arguably harder-to-treat population, with possibly better safety to boot.Īt Ash it is adding seven patients to bring the evaluable dataset to 38 as of an October 31 cutoff. Kite Pharma Expands R&D Team, Appoints Dr. ![]() The last time Arcellx presented CART-ddBCMA data, at Asco in June, it argued that the project, which is autologous but uses an artificial binding domain to hit BCMA, had “best-in-class potential”. The Gilead deal adds a key endorsement.īeing competitive in this space is especially hard given the huge number of BCMA-targeting projects in development, and the added availability as of October of J&J’s Tecvayli, a T-cell engaging MAb. J&J’s approved rival BCMA-directed Car-T therapy, Carvykti, has set a high bar which, once again, CART-ddBCMA seems to have met. Friday’s licensing deal saw the big biotech hand across $225m in cash and make a $100m equity investment for rights to the project.Īn investor update made available ahead of Arcellx’s Ash poster on Sunday sheds more light on the latest cut of the phase 1 CART-ddBCMA study that secured Gilead as a partner. Wiezorek, M.D., M.S. With Arcellx’s CART-ddBCMA maintaining its 100% track record of putting multiple myeloma patients into remission, according to data being presented at Ash, Gilead heard enough to sign on the dotted line. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the appointment of Jeffrey S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |